13 completed, 4 terminated, 1 withdrawn. 11 Phase 2, 10 Phase 1, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Terminated 4, Withdrawn 1 |
| Phase 1 | 10 | Completed 8, Terminated 2 |
| Not applicable | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Colorectal Tumors: new trials by email Literature Review of Colorectal Tumors trials Research Report on Colorectal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, trametinib, Ribociclib - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 74 | 2022-10-24 | 2026-10-21 |
| A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors Cohort 1: HFCS (fructose) fed, Cohort 2: D-Xylose (xylose-fed) - Colorectal Tumors | Not applicable | Completed | Weill Medical College of Cornell University | 12 | 2022-02-16 | 2024-11-06 |
| VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) Vascular Biogenics (VB)-111, Nivolumab - Metastatic Colorectal Cancer, Colorectal Neoplasms | Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2020-08-09 | 2026-03-10 |
| Effect of Intravenous Infusion of Lidocaine on Patients Undergoing Radical Resection of Colorectal Tumors Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation - Colorectal Tumors, Lidocaine | Not applicable | Completed | Affiliated Hospital of Nantong University | 100 | 2020-03-24 | 2023-08-02 |
| A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment NUC-3373 + leucovorin, NUC-3373, NUFOX - Colorectal Cancer, Colorectal Neoplasms | Phase 1 / Phase 2 | Completed | NuCana plc | 111 | 2018-10-05 | 2025-04-23 |
| An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread Nivolumab, Trametinib, Ipilimumab - Colorectal Cancer, Colorectal Tumors | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 325 | 2018-01-31 | 2025-12-03 |
| Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 Avelumab, Ad-CEA vaccine, Bevacizumab - Colorectal Tumors, Colorectal Neoplasms | Phase 2 | Terminated | National Cancer Institute (NCI) | 30 | 2017-04-05 | 2021-12-20 |
| Predictive Factors for Anastomotic Leakage After Colorectal Surgery No interventions, only data collection - Anastomotic Leakage, Colorectal Cancer | Completed | Maastricht University Medical Center | 774 | 2015-08-01 | 2021-09-29 | |
| Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI) DC Vaccine - Colorectal Neoplasms, Colorectal Cancer | Phase 1 | Completed | Pawel Kalinski | 6 | 2013-01-01 | 2017-09-26 |
| Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population Colorectal Neoplasms, Adenoma | Completed | Cairo University | 316 | 2012-12-01 | 2015-05-06 | |
| Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2) - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 15 | 2012-10-01 | 2023-10-27 |
| ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer ISIS 183750, Irinotecan - Colorectal Neoplasms, Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 24 | 2012-08-01 | 2016-04-25 |
| A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin Glutamine - Colorectal Carcinoma, Neoplasms, Colorectal | Phase 2 | Withdrawn | AHS Cancer Control Alberta | 2011-10-01 | 2016-02-24 | |
| Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome Antibiotic lavage, Normal saline lavage - Colorectal Tumors | Phase 3 | Completed | Hospital General Universitario Elche | 106 | 2011-01-01 | 2015-03-26 |
| Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer Panitumumab, Irinotecan, Everolimus - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | The Queen Elizabeth Hospital | 49 | 2010-06-01 | 2017-11-06 |
| Dendritic Cell Vaccination for Patients with Solid Tumors autologous dendritic cell vaccination - Glioblastoma, Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | University Hospital, Antwerp | 48 | 2010-05-03 | 2024-12-09 |
| Nelfinavir, a Phase I/Phase II Rectal Cancer Study nelfinavir - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | Maastricht Radiation Oncology | 15 | 2008-09-01 | 2014-12-08 |
| A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer RAD001, Cetuximab, Irinotecan - Colorectal Cancer, Colorectal Carcinoma | Phase 1 | Completed | Novartis Pharmaceuticals | 19 | 2007-05-01 | 2012-11-02 |
Colorectal Neoplasms (18) · Neoplasm Metastasis (2) · Recurrence (2) · Adenoma (1) · Anastomotic Leak (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Disease (1) · Glioblastoma (1) · Inflammation (1) · Mesothelioma, Malignant (1) · Neoplasm Micrometastasis (1)
Colonic Diseases (18) · Digestive System Diseases (18) · Digestive System Neoplasms (18) · Gastrointestinal Diseases (18) · Gastrointestinal Neoplasms (18) · Intestinal Diseases (18) · Intestinal Neoplasms (18) · Neoplasms by Site (18) · Rectal Diseases (18) · Neoplasms (17) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Neoplastic Processes (3)
Irinotecan (4) · Cetuximab (3) · Bevacizumab (2) · Everolimus (2) · Leucovorin (2) · Nivolumab (2) · Oxaliplatin (2) · Panitumumab (2) · trametinib (2) · Capecitabine (1) · Celecoxib (1) · Fluorouracil (1) · Fructose (1) · Glutamine (1) · Interferon alpha-2 (1)
National Cancer Institute (NCI) (3) · Novartis Pharmaceuticals (2) · AHS Cancer Control Alberta (1) · Affiliated Hospital of Nantong University (1) · Bristol-Myers Squibb (1) · Cairo University (1) · Hospital General Universitario Elche (1) · Maastricht Radiation Oncology (1) · Maastricht University Medical Center (1) · NuCana plc (1) · Pawel Kalinski (1) · Roswell Park Cancer Institute (1) · The Queen Elizabeth Hospital (1) · University Hospital, Antwerp (1) · Weill Medical College of Cornell University (1)
United States (10) · Belgium (3) · Australia (2) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Spain (2) · Argentina (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · Egypt (1) · Singapore (1)
Tim F Greten, M.D. (2) · Amanda Townsend, MBBS (1) · Amer H Zureikat, MD (1) · David L. Bartlett, MD (1) · Elisabeth Oelmann, MD PhD (1) · Hany M Shehab, MD, MRCP (1) · Jaime Ruiz-Tovar, MD, PhD (1) · Julius Y Strauss, M.D. (1) · Mehraneh D Jafari, MD (1) · Michael Sawyer, MD (1) · Nicole Bouvy, MD, PhD (1) · Ph. Lambin, MD PhD (1)
PMID 27194579, PMID 27282451, PMID 38184304
2017 (2), 2023 (1), R01CA134633 (1)